Can I read CA 15-3 in patients with locoregional and metastatic breast carcinoma on EtoBox?

CA 15-3 in patients with locoregional and metastatic breast carcinoma by J. G. Geraghty; E. C. Coveney; F. Sherry; N. J. O'Higgins; M. J. Dufy is a Medicine article available to read on EtoBox.

What is CA 15-3 in patients with locoregional and metastatic breast carcinoma about?

Background. The value of circulating CA 15-3 levels was assessed in 129 patients with recurrent breast carcinoma. Methods. Patients were divided into four subgroups, according to the following: Group A, locoregional recurrence alone; Group B, locoregional and subsequent systemic recurrence; Group C, combined locoregional and systemic recurrence; and Group D, differing sites of systemic disease. Results. One of 14 patients with locoregional disease alone had increased levels of CA 15-3 (> 25 U/ml). However, 96% of patients (22 of 23 patients) with combined local and systemic disease had increased tumor marker levels. The difference in CA 15-3 levels in patients with combined disease compared with patients with local disease alone was statistically significant (117.0 versus 17.5 U/ml, respectively; P < 0.02). Twentyfour patients with locoregional recurrence later had distant metastasis develop. In this group, patients with an increased CA 15-3 value had a significantly shorter lead time to the development of distant metastases compared with patients with normal tumor marker levels (20.8 f 3.3 versus 10.3 k 2.7 months, respectively; P < 0.03). CA 15-3 values at diagnosis were increase

Who reads CA 15-3 in patients with locoregional and metastatic breast carcinoma?

Author

J. G. Geraghty; E. C. Coveney; F. Sherry; N. J. O'Higgins; M. J. Dufy

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)

Published

1992

Language

EN

Field

Medicine (Health Sciences)